



Thursday, July 14th, 2016
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 114

Board Members Present

Jay Aldus, D.D.S.
Keith Tolman, M.D.
Steve Lore, M.D.
Holly Gurgle, Pharm.D.

Jennifer Brinton, M.D., Board Chair
Susan Siegfried, M.D.
Ben Berrett, Pharm D
Kumar Shah, M.Sc., P.Eng.

Board Members Excused:

Katherine Smith, Pharm D
Neal Catalano, Pharm D

Michael Symond, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Chad Hope, Pharm.D.
Alyssa Pitts, R.N.
Merelynn Berrett, R.N

Heather Santacruz, R.N.
Bryan Larson, Pharm.D.
Megan Schlappi, C.Ph.T.

Other Individuals Present:

Joanita Lake, UofU*
Caroline Kicklighter, Novartis
Don Mccafferey, Vertex
Paul Williams, Takeda
Lovell Robinson, Abbvie
Charissa Anne, J+J
Risa Reuscher, Amgen
Joanne Lafleur, UofU
Michael Faithe, Amgen
Scott Clegg, Lilly
Laura Britton, UUHP

Chris Anstead, Amgen
Becky Gonzales, ViiV Healthcare
Lisa Allen, Vertex
Linda Craig, Amgen
Ashley Polce, Abbvie
Russell Vinik, UofU
Sal Lufaso, Horizon
Lori Howarth, Bayer
Cody Ball, Select Health
David Copeland, Sego

*UofU = University of Utah

Meeting conducted by: Jennifer Brinton, M.D.

1. Welcome & Housekeeping: Jennifer Brinton opened the meeting and reminded everyone to sign the rosters. Robyn Seely asked the board members for their input on any future DUR meeting topics they may want to see reviewed.

2. Review and Approval of May Minutes: Kumar Shah motioned to approve the minutes from May. Steve Lore seconded. 7 out 8 board members approved. Keith Tolman abstained.

3. 9 Month Review: Hyalurnoic Acid derivatives, Orkambi & Kalydeco and PCSK9

Inhibitors: Robyn Seely said that the previously set criteria on these medications is working well with no problems.

4. Reconsideration of Prior Authorization Criteria: The Board reviewed outdated clinical Prior Authorization (PA) criteria. They motioned to remove the PA's for the following medications: Nucynta and Nucynta ER, Cytokine Modulators (Humira, Enbrel, Actemra, Cimzia, Cosentyx, Entyvio, Kineret, Orencia, Otezla, Remicade, Simponi, Stelera, Taltz, Xeljanz IR/ER, and Rituxan). Keith Tolman made the motion to remove the PA criteria. Steve Lore seconded. All in favor.

5. Short Acting Opiates: Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about the three androgen products. Data was also presented about the utilization of the drugs in the Utah Medicaid population.

6. Public Comments:

- a) Amgen: No comment
- b) Pfizer: No comment
- c) Cystic Fibrosis Foundation: Robyn Seely read a letter previously sent to the board from the Cystic Fibrosis Foundation recommending that Utah Medicaid classify Orkambi and Kalydeco as preferred on the PDL.
- d) Abbvie: Ashley Polce discussed the product Humira and its two new indications.
- e) Healthy U: Russel Vinik discussed the cost vs. benefits of Orkambi and Kalydeco.

7. Board Discussion:

- a) Jennifer Brinton noted that physicians have to do training regarding opiates, but nowhere in the training does it discuss how the number of pills being prescribed is a problem.
- b) Chad Hope reminded the board that this discussion was about acute and chronic non-cancer pain. A cancer diagnosis on a pharmacy claim bypasses any edits, while hospice patients receive their medications through hospice. Chad also explained to the board that Medicaid's current edits on short acting opiates allow for a client to fill 180 tablets per month for any drug.
- c) Keith Tolman discussed the negative effects seen with chronic opioid use. He also noted that quality of life and function are not addressed in any of the opiate studies.
- d) Chad Hope explained to the board that Medicaid does have the ability in their system to edit on days' supply and that some States limit the first fill to 7 days or less.
- e) Steve Lore discussed his work with patients who have osteoarthritis. He explained that some patients have osteoarthritis that is inoperable and they simply cannot get out of bed without some sort of pain reliever. He asked the board how the patients were going to be treated if they did not have access to opiates.
- f) Keith Tolman and Steve Lore debated the pros and cons of limiting member's access to opiates. They talked about how physicians should treat the patients, not treat the data. They also discussed alternative therapy and the limitations that may occur.
- g) Jennifer Brinton notified the board that time was up. She suggested continuing this discussion next month.
- h) Keith Tolman made a motion to limit short acting opioid prescriptions to 7 days for the initial fill. If the patient needs to be on the medication longer than 7 days, there must be some justification from the physician. Kumar Shah Seconded. All in favor.

8. Public Meeting Adjourned

9. Next meeting is scheduled for August 11th, 2016. Long Acting Opiates will be discussed.

Audio recordings of DUR meetings are available online at:

<https://medicaid.utah.gov/pharmacy/drugutilizationreviewboard?p=DUR%20Board%20Audio%20Recordings/>

Pending